High Th1/Th2 ratio in patients with multiple myeloma

Ogawara, Hatsue; Handa, Hiroshi; Yamazaki, Tohru; Toda, Takuma; Yoshida, Kan; Nishimoto, Natsumi; Al-ma’Quol, Wedad Hamdi Saleh; Kaneko, Yoriaki; Maekawa, Takafumi; Tsukamoto, Norifumi; Nojima, Yoshihisa; Matsumoto, Morio; Sawamura, Morio; Murakami, Hirokazu

doi:10.1016/j.leukres.2004.06.003

Cited by 76 publications

(50 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the majority of newly diagnosed MM patients are elderly, gradual immunosenescence as well as decline in functional status predisposes them to infections [54,55]. This risk is compounded by the acquired deficits in humoral and cellular immunity induced by the MM itself [56][57][58][59]. The MM-directed therapies also have the ability to increase the risk of infections due to therapy-related neutropenia and cellular immunity suppression from high-dose steroids [53].…”

Section: Do Avoid and Manage Infectionmentioning

confidence: 99%

Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma

et al. 2015

View full text Add to dashboard Cite

In the era of novel biological agents, multiple myeloma (MM) is often approached as a chronic condition. While survival continues to improve, population‐level data indicate that early mortality remains a substantial barrier to advances in MM outcomes. Here we provide “do's and don'ts” management recommendations that may minimize the risk of early mortality and ensure that patients have the opportunity to benefit from the long term impact of new effective MM agents. Such recommendations encompass the early introduction of novel agents even in the presence of comorbidities and advanced age and aggressive management of MM‐related complications. Am. J. Hematol. 91:101–108, 2016. © 2015 Wiley Periodicals, Inc.

show abstract

Section: Do Avoid and Manage Infectionmentioning

confidence: 99%

Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…CD4 helper T cells and CD8 cytotoxic T cells (CTLs), play a crucial role in anti-tumor immunity. In myeloma patients, several CD4 and CD8 T-cell abnormalities have been described, most frequently a decrease of CD4 T cells [13][14][15][16][17][18]. Specifically, Schutt et al reported reduced levels of memory CD4 T cells (CD4 + CD45RO + ), as well as activated CD3 + HLA-DR + T cells in the blood of MM patients [18].…”

Section: T Cellsmentioning

confidence: 99%

“…Th1 cells produce interferon (IFN)-γ and interleukin (IL)-2 and play a role in cellmediated immunity, while Th2 cells promote humoral immunity and produce IL-4, IL-5, IL-6, IL-10, IL-13 and IL-25 [20,21]. In myeloma patients, abnormal Th1/Th2 ratios have been reported [17,20,22]. Sharma et al describe a polarization towards Th2 cytokines along with Th1 suppression [22] while others report a decrease of Th2 cells, leading to an increased Th1/Th2 ratio [17].…”

Section: T Cellsmentioning

confidence: 99%

“…In myeloma patients, abnormal Th1/Th2 ratios have been reported [17,20,22]. Sharma et al describe a polarization towards Th2 cytokines along with Th1 suppression [22] while others report a decrease of Th2 cells, leading to an increased Th1/Th2 ratio [17]. The observations of Sharma et al are supported by findings in a murine MM model in which anti-myeloma activity of Th1 cells was reported [23], and by observations suggesting an attenuation of Th1 responses induced by MM cells [24].…”

Section: T Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Cellular immunotherapy in multiple myeloma: Lessons from preclinical models

Binsfeld

Fostier

Muller

et al. 2014

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

The majority of multiple myeloma patients relapse with the current treatment strategies, raising the need for alternative therapeutic approaches. Cellular immunotherapy is a rapidly evolving field and currently being translated into clinical trials with encouraging results in several cancer types, including multiple myeloma. Murine multiple myeloma models are of critical importance for the development and refinement of cellular immunotherapy. In this review, we summarize the immune cell changes that occur in multiple myeloma patients and we discuss the cell-based immunotherapies that have been tested in multiple myeloma, with a focus on murine models.

show abstract

“…These tumor-derived factors can also modulate anti-tumor host immune responses, including the abrogation of DC function, by constitutive activation of the signal transducer and activator of transcription 3 (STAT3) (Yu et al, 2007). Impairment in both humoral and cellular immunity in MM is associated with impaired B cell differentiation and antibody responses (Brown et al, 2001), reduced T cell numbers specifically CD4 + T cells and abnormal Th1/Th2 CD4 + T cell ratio (Ogawara et al, 2005), impaired CTL responses (Maecker et al, 2003), and dysfunction of NK cells (Jarahian et al, 2007) and NKT cells (Dhodapkar et al, 2003). In addition, dysregulation of natural CD4 + CD25 + T regulatory (Treg) has been reported (Prabhala et al, 2006).…”

Section: Immune Disorder In MMmentioning

confidence: 99%